Beigene адр (ONC) Tmuɣli n wazal
Beigene
Ṛṛbem n lḥedd$360.85Yettwalemmaḍ 25 Sep 2026
Beddel+0.24%
Asnulfu n AI: ONC
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
BeiGene, Ltd. is a commercial-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of molecularly targeted and immuno-oncology therapies for the treatment of cancer. BeiGene serves patients worldwide.
